Home / Health / New Yellow Fever Vaccine Shows Promise
New Yellow Fever Vaccine Shows Promise
12 Apr
Summary
- A new vaccine, vYF, offers comparable protection to existing yellow fever vaccines.
- vYF vaccine is produced using Vero cells for higher yields and efficiency.
- The vaccine demonstrated a 99.7% protective antibody rate in a clinical trial.
A new vaccine candidate, vYF, developed by Sanofi, is emerging as a significant tool in the global fight against yellow fever. This disease, spread by infected mosquitoes, claims between 29,000 and 60,000 lives each year, despite the availability of vaccines.
The vYF vaccine utilizes Vero cells for production, a method that allows for more efficient and higher yields compared to traditional vaccine manufacturing. This advancement is crucial given past instances where global emergency supplies were depleted, leading to the use of fractional vaccine doses.
Clinical trials involving 485 healthy adults directly compared vYF against the established YF-VAX. The results indicated that vYF was highly effective, with 99.7% of recipients developing protective antibodies within 28 days, a rate nearly identical to YF-VAX's 99.4% success.
Antibody levels in both vaccine groups peaked similarly and declined at comparable rates over a year. Importantly, no significant safety concerns were reported, with side effects being mild. Upon approval, vYF is expected to provide a scalable solution to prevent future vaccine shortages and aid in controlling worldwide outbreaks.
